
Key opinion leaders in urology share their credentials and highlight the general structure of their institution in regard to prostate cancer management.

Key opinion leaders in urology share their credentials and highlight the general structure of their institution in regard to prostate cancer management.

Focused discussion on the quality of training and onboarding of physicians who manage advanced prostate cancer within a variety of institutions and settings.

Switching their focus to the treatment armamentarium, expert panelists reflect on selection and sequencing of therapy for patients with advanced prostate cancer.

Digging into the logistics of advanced prostate cancer management, keynote speakers consider challenges faced with the electronic systems used to request or order therapy.

A brief review of the role that testosterone measurements play, amidst other monitoring strategies, in assessing for treatment failure in advanced prostate cancer.

Centering discussion on insurance and reimbursement, key opinion leaders in prostate cancer management consider the current state of coverage for GnRH agonists/antagonists.

A more focused discussion on the specific challenges physicians or patients may face when seeking coverage or reimbursement for GnRH agonists/antagonists in prostate cancer.

Experts in urology share a brief conversation on recent and future legislation for insurance coverage and reimbursement, considering how it may impact their management of prostate cancer.

Shared insight on the current state of telehealth and how its use affects treatment selection and followup for patients with advanced prostate cancer.

Expert panelists share their perspectives on recent challenges with staffing and turnover in their urology practice and consider how these particular barriers may be overcome, including recruiting and hiring additional advanced practice providers.

Closing out their discussion on how treatment and management of advanced prostate cancer affects their clinical practice, expert urologists consider how the therapeutic landscape continues to evolve and look toward future evolutions in care.